Introduction: We investigated the prevalence, predictors of and effect of Antiretroviral Therapy (ART) regimen on cardiometabolic risk among
Introduction
Sub Saharan Africa (SSA) has the highest burden of HIV/AIDS, with an estimated 25.8 million people living with HIV and about 1.4 million new infections in 2014 [1] . Antiretroviral therapy (ART) has improved the quality of life of people living with HIV (PLWH) and has improved life expectancy substantially [2, 3] . By June 2015, 5.8 million PLWH were receiving ART globally, of which 10.7 million were in SSA [1] . As people on ART live longer, challenges of longterm HIV infection, lifestyle changes, aging and the toxic effects of ART, are emerging. Risk factors for cardiovascular disease (CVD) among PLWH may be similar to the general population and include family history, age, male gender, hypertension, smoking, obesity, Diabetes mellitus and hyperlipidemia [4] . PLWH on ART have an estimated 10-year CVD risk greater than 20% [5] . The expected deaths attributable to CVD are projected to double to 2.4 million in 2030 relative to reports from 2000 [6] . Mortality due to CVD in SSA including Uganda is estimated to be threefold higher than in Western Europe [7] . In industrialised countries where ART has been provided for longer periods, ART agents particularly Protease Inhibitors (PI), have been associated with cardiometabolic risk factors, including impaired glucose metabolism, dyslipidemia, obesity and hypertension [8] but this has not been demonstrated in African settings. There is evidence to suggest that baseline metabolic profiles and associations between HIV, ART and cardiometabolic risk factors may differ between populations [9] . In Uganda, about 31700 deaths in 2002 were due to CVD and there is evidence of increasing CVD-related mortality from verbal autopsy data from among HIV infected people [10] . Conversely, a homebased cross-sectional study in eastern Uganda reported no effect of ART on CVD, but that study had few participants on ART, for a shorter duration and did not examine the specific effects of a PI regimen [11] . HIV prevalence in Uganda in 2014 was 7.4% and about 0.75 million (50%) of the 1.5 million PLWH were on ART of whom about 10% had HIV viral load above 1000 copies/ml [12] .
The roll out of HIV viral load testing in Uganda and other African countries will increase detection of individuals with virological failure needing second line PI based ART [13] . In this study, we investigated the prevalence and predictors of, and the effect of ART on cardiometabolic risk among HIV-positive individuals who have been receiving ART for up to a decade. We specifically compared the adjusted mean differences and the risk of the various cardiometabolic risk factors between participants on a PI containing ART regimen and non PI ART regimen against the confounding effect of demographic, socio economic and behavioral factors. 
Methods

Study population:
The study sample selection was based on nonprobability sampling of all HIV-positive adults aged 18 years and above, from two former HIV cohorts; the DART trial and RCC, who were receiving ART and consenting to undergo all study procedures.
Study information was given to potential participants by a study clerk. Individuals who were too sick to undergo study procedures or unable to give consent were excluded. Participants were either taking a PI containing ART regimen or Non PI containing regimen.
Non PI regimen included a standard two Nucleoside Reverse Transcriptase inhibitor (NRTI) and one Non-NRTI. Some participants from the DART trial cohort were taking a triple nucleoside therapy consisting of 3 NRTI agents. The PI containing regimen consisted of a ritonavir boosted PI mainly Lopinavir in combination with one or two NRTI. Hypertension was defined as systolic blood pressure (SBP)>140 mmHg and/or diastolic blood (DBP) pressure>90 mmHg or being on anti-hypertensive medication [19, 20] . Dyslipidemia was defined as
Measurements
mmol/L or Tc-HDL ratio>5.1 or being on lipid lowering medicine [19, 20] . Hyperglycemia was defined as fasting blood glucose >7mmol/L or being on treatment for diabetes mellitus. Abdominal obesity was assessed using waist-hip ratio (WHR) cutoffs of 0.95 for men and 0.85 for women [21] 
Discussion
In our Ugandan cohort of people on long-term ART, more than a half of participants had abdominal obesity, about one third had high BMI, high Tc, low HDL, high AIP, and almost a quarter had high TG, FHS > 10% and hypertension. Few participants had hyperglycemia.
Age, gender, physical activity, high viral load and PI-based ART regimen significantly affected cardiometabolic risk factors. The prevalence of hypertension compares with that reported in a South
African study with similar median age [21], but higher than that reported from an ART cohort of younger adults in Rakai-Uganda (8.0%), Mbarara-Uganda (5.2%) and Kenya (8.8%) albeit lower than what was reported from Urban Uganda (27%)(24-26).
Although the differences might be attributed to variation in population characteristics and settings, the prevalence exceeded that from the background general population cohort (GPC)-13%
[10]. The risk of hypertension was higher among individuals on non 
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